JUN 01, 2017 04:21 PM PDT

A New Test to Measure if HIV Can Be "Cured"

WRITTEN BY: Kara Marker

When is someone “cured” of HIV? If there is such a state reachable with drug therapies, how can a doctor tell? The problem stems from HIV’s tendency to hide dormant inside of immune cells - CD4+ T cells specifically - that make remaining viruses leftover after antiviral treatment difficult to detect.

 

Dr. Anwesha Sanyal indicates HIV-infected cells collecting at the bottom of a vial being prepared for Pitt Public Health's TZA test. Credit: Tim Betler/UPMC

 

From the University of Pittsburgh Schools of the Health Sciences, researchers have published a new study in the journal Nature Medicine describing their new test design for detecting dormant HIV.

 

"Globally there are substantial efforts to cure people of HIV by finding ways to eradicate this latent reservoir of virus that stubbornly persists in patients, despite our best therapies," said senior author Phalguni Gupta, PhD. "But those efforts aren't going to progress if we don't have tests that are sensitive and practical enough to tell doctors if someone is truly cured."

 

The existing test most experts rely on is the “quantitative viral outgrowth assay” or “Q-VOA.” Its shortcomings? Q-VOA requires a large volume of blood, is labor-intensive, time-consuming, and expensive, and the estimate the test provides usually doesn’t tell the whole story.

 

The Pittsburgh researchers instead offer the new “TZA” test to detect dormant HIV, which improves upon virtually all of Q-VOA’s weaknesses. The test works by detecting activity of a unique gene that is only expressed when HIV is currently replicating. TZA produces results in one week - Q-VOA takes two - and is one-third of the cost of Q-VOA. TZA also requires a much smaller amount of blood for testing and is less labor-intensive.

Thanks to the new test, the Pittsburgh researchers discovered that the amount of dormant HIV existing in “nearly cured” people is 70 times as much as experts previously thought.

"Using this test, we demonstrated that asymptomatic patients on antiretroviral therapy carry a much larger HIV reservoir than previous estimates--as much as 70 times what the Q-VOA test was detecting," Gupta explained. "Because these tests have different ways to measure HIV that is capable of replicating, it is likely beneficial to have both available as scientists strive toward a cure."

 

The new TZA test could soon be the most commonly-used test to detect specific numbers of latent HIV in the body. With these measurements made, doctors can alter an HIV patient’s treatment plan to send them on a better, more specialized path to a true “cure.”

 

Source: University of Pittsburgh Schools of the Health Sciences

About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
AUG 29, 2018
Immunology
AUG 29, 2018
Immune System Prioritizes Response when Faced with Multiple Threats
The Innate Immune response prioritizes lung infection and cell repair over other threats in both infants and adults....
SEP 26, 2018
Videos
SEP 26, 2018
Cancer Immunotherapy
Video illustration about how tumor cells are sensed and destroyed by the immune system and how tumors evolve and detect immune-mediated eliminations, as well as iimmunotherapies associated....
OCT 09, 2018
Drug Discovery
OCT 09, 2018
'Copper Antibiotic Peptide' Effective in Eradicating Tuberculosis
The bacterium responsible for Tuberculosis has found a way to avoid antibiotics by hiding inside the macrophages which are the specific immune cells that a...
NOV 05, 2018
Drug Discovery
NOV 05, 2018
Anti-Parasitic Drug Improves Long-term Clinical Outcomes in Chagas Disease
In a recent study published in PLOS Neglected Tropical Diseases, an anti-parasite drug by the name of ‘benznidazole’ may hold potential in impr...
NOV 07, 2018
Immunology
NOV 07, 2018
Herd Protection Against Measles
A 26-year-old leukemia patient dies from exposure to measles. Herd immunity can offer a level of protection for those with impaired immune systems....
NOV 19, 2018
Cell & Molecular Biology
NOV 19, 2018
How Mitochondria can Help the Cell Fight Pathogens
Some pathogens can get around out bodies' natural defense mechanisms. So our body developed a Plan B....
Loading Comments...